An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases | MicrobiomeTrials← Back to trialsNCT06664814
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-10-29Est. Completion: 2030-11-11
Enrollment target: 30 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Antiphospholipid (aPL)-PositiveRheumatic ArthritisCeliac DiseaseFocal Segmental Glomerulosclerosis (FSGS)Membranous NephropathyCrohn Disease (CD)Type 1 Diabetes MellitusAlport SyndromePompe DiseaseAlzheimer s DiseaseUrea Cycle DisorderSystem Lupus ErythematosusHyperlipidemiaInherited ThrombophiliaSickle Cell Disease (SCD)Parkinson Disease (PD)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and b…
Amman, JordanEst. completion Oct 2028
Immunoglobulin A Nephropathy (IgAN)
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
San Francisco, United StatesEst. completion Jul 12, 2030